KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Long-Term Investments: 2011-2024

Historic Long-Term Investments for Nektar Therapeutics (NKTR) over the last 10 years, with Dec 2024 value amounting to $13.9 million.

  • Nektar Therapeutics' Long-Term Investments rose 6.61% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 6.61%. This contributed to the annual value of $13.9 million for FY2024, which is 46.30% down from last year.
  • As of FY2024, Nektar Therapeutics' Long-Term Investments stood at $13.9 million, which was down 46.30% from $25.8 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Long-Term Investments ranged from a high of $136.7 million in FY2020 and a low of $13.9 million during FY2024.
  • In the last 2 years, Nektar Therapeutics' Long-Term Investments had a median value of $19.8 million in 2023 and averaged $19.8 million.
  • Data for Nektar Therapeutics' Long-Term Investments shows a maximum YoY slumped of 52.56% (in 2021) over the last 5 years.
  • Yearly analysis of 4 years shows Nektar Therapeutics' Long-Term Investments stood at $136.7 million in 2020, then slumped by 52.56% to $64.8 million in 2021, then reached $25.8 million in 2023, then slumped by 46.30% to $13.9 million in 2024.